Signal Bureau What’s happening · what the record shows

KRAS Mutant Colorectal Cancer

A topic on our watch list — we track its coverage across 1 domain, including Pubmed Targeted.

If KRAS Mutant Colorectal Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.

What’s changed

Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. · Cell Death Dis · 2026-07-06
Pyra-Metho-Carnil Suppresses CD73-associated Macrophage Infiltration in KRAS-mutant Colorectal Cancer. · Anticancer Res · 2026-08-01

Ask the engine about KRAS Mutant Colorectal Cancer ＋ Track KRAS Mutant Colorectal Cancer for a daily read

Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Jul 31, 6:34 AM PT